PT  - JOURNAL ARTICLE
AU  - TAKAAKI ARIGAMI
AU  - DAISUKE MATSUSHITA
AU  - KEISHI OKUBO
AU  - TAKAKO TANAKA
AU  - KEN SASAKI
AU  - YUSUKE TSURUDA
AU  - YOSHIAKI KITA
AU  - SHINICHIRO MORI
AU  - HIROSHI KURAHARA
AU  - YOSHIKAZU UENOSONO
AU  - TAKAO OHTSUKA
TI  - Changes in Chemotherapeutic Strategies and Their Prognostic Impact in Patients With Advanced Gastric Cancer
AID  - 10.21873/invivo.12718
DP  - 2022 Jan 01
TA  - In Vivo
PG  - 409--415
VI  - 36
IP  - 1
4099  - http://iv.iiarjournals.org/content/36/1/409.short
4100  - http://iv.iiarjournals.org/content/36/1/409.full
SO  - In Vivo2022 Jan 01; 36
AB  - Background/Aim: To investigate changes in post-progression chemotherapy (PPC) before and after nivolumab approval and determine their prognostic impact. Patients and Methods: A total of 146 patients with unresectable gastric cancer who had at least progressive disease after first- and/or second-line chemotherapy were retrospectively enrolled. Results: Among the 146 patients, 46 and 23 received ramucirumab and nivolumab, respectively. Moreover, 95 and 62 patients received PPC after first- and second-line chemotherapy, respectively. Group B (i.e., at least chemotherapy after nivolumab approval) had significantly higher proportions of patients receiving ramucirumab therapy, nivolumab therapy, and PPC after first- or second-line chemotherapy compared to group A (i.e., termination of chemotherapy before nivolumab approval). Group A had significantly poorer prognosis than group B. Multivariate analysis showed that age, number of distant metastatic sites, and ramucirumab therapy were independent prognostic factors. Conclusion: Changes in chemotherapeutic strategies, including PPC, might contribute to improved prognosis in patients with advanced gastric cancer.